140 related articles for article (PubMed ID: 347106)
1. Levamisole in the treatment of non-invasive and invasive bladder cancer: a preliminary report.
Smith RB; Dekernion J; Baron B; Skinner DG; Kaufman JJ
J Urol; 1978 Mar; 119(3):347-9. PubMed ID: 347106
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report of the use of levamisole in the treatment of bladder cancer.
Smith RB; deKernion J; Lincoln B; Skinner DG; Kaufman JJ
Cancer Treat Rep; 1978 Nov; 62(11):1709-14. PubMed ID: 365325
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of orally administered levamisole on random monocyte motility and chemotaxis in man.
Nathanson SD; Zamfirescu PL; Portaro JK; deKernion JB; Fahey JL
J Natl Cancer Inst; 1978 Aug; 61(2):301-6. PubMed ID: 355647
[TBL] [Abstract][Full Text] [Related]
4. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
5. Specific red cell adherence test and unspecific immune response in patients with superficial bladder cancer.
Jakse G; Hofstädter F; Märk R
Urol Int; 1981; 36(3):171-7. PubMed ID: 7025414
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report.
Wanebo HJ; Hilal EY; Pinsky CM; Strong EW; Mike V; Hirshaut Y; Oettgen HF
Cancer Treat Rep; 1978 Nov; 62(11):1663-9. PubMed ID: 365322
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of tumors of the urinary bladder with so-called immunopotentiators].
Tsujimura S; Kato J; Ueda K; Ohtaguro K
Hinyokika Kiyo; 1983 Jan; 29(1):9-15. PubMed ID: 6677093
[TBL] [Abstract][Full Text] [Related]
8. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
[TBL] [Abstract][Full Text] [Related]
9. Levamisole: a double blind immunological study.
Webster DJ; Whitehead RH; Richardson G; Hughes LE
Anticancer Res; 1982; 2(1-2):29-32. PubMed ID: 7051958
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report.
Wanebo HJ; Hilal EY; Strong EW; Pinsky CM; Mike V; Oettgen HF
Recent Results Cancer Res; 1978; 68():324-33. PubMed ID: 379937
[TBL] [Abstract][Full Text] [Related]
11. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
12. Levamisole in Crohn's disease--a double-blind controlled trial.
Wesdorp E; Schellekens PT; Weening RS; Meuwissen SG; Tytgat GN
Digestion; 1978; 18(3-4):186-91. PubMed ID: 367851
[TBL] [Abstract][Full Text] [Related]
13. Levamisole in squamous cell carcinoma of the head and neck.
Olivari AJ; Glait HM; Guardo A; Califano L; Pradier R
Cancer Treat Rep; 1979 Jun; 63(6):983-90. PubMed ID: 380804
[TBL] [Abstract][Full Text] [Related]
14. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
[TBL] [Abstract][Full Text] [Related]
19. Immunological responsiveness in patients with bladder cancer.
Fahey JL; Brosman S; Dorey F
Cancer Res; 1977 Aug; 37(8 Pt 2):2875-8. PubMed ID: 872117
[TBL] [Abstract][Full Text] [Related]
20. Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia.
Advani SH; Gulwani B; Ghogale SG; Shetye MR; Gangal SG
Oncology; 1985; 42(5):275-81. PubMed ID: 3897932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
